目的：观察长春西汀注射液联合依达拉奉治疗急性腔隙性脑梗死的临床疗效。方法96例急性腔隙性脑梗死患者随机分为观察组和对照组，各48例，两组在治疗相应基础病和常规抗凝、抗血小板聚集治疗基础上，观察组加用长春西汀注射液及依达拉奉进行治疗，对照组加用倍他司汀注射液及血塞通注射液进行治疗，疗程2周。观察两组治疗效果、记录不良反应、评估安全性。治疗前和治疗2周后进行欧洲脑卒中评分(ESS)，用积分评判疗效。结果观察组总有效率为93.8%，优于对照组81.3%，差异具有统计学意义(P<0.05)。两组药物无明显不良反应。结论相比使用倍他司汀+血塞通，长春西汀联合依达拉奉治疗急性腔隙性脑梗死疗效确切，安全性好，值得临床推广应用。%Objective To investigate the clinical effect of vinpocetine combined with edaravone in the treatment of acute lacunar infarction.Methods A total of 96 acute lacunar infarction patients were randomly divided into observation group and control group, with 48 cases in each group. On the basis of treatment for background disease, conventional anticoagulation, and anti-platelet aggregation, the observation group received vinpocetine injection combined with edaravone for treatment, and the control group received betahistine injection and Xuesaitong injection for treatment. Treatment lasted for 2 weeks. Curative effects of the two groups were observed, their adverse reactions were recorded and safety was evaluated. The European stroke scale (ESS) was applied before treatment and in 2 weeks after treatment, and their scores were used for effects evaluation.ResultsTotal effective rate of the observation group was 93.8%, which was much better than 81.3% of the control group. The difference had statistical significance (P<0.05). Both groups had no obvious adverse reactions.Conclusion Compared with betahistine + Xuesaitong, the combination of vinpocetine and edaravone provides precise effect and good safety in treating acute lacunar infarction. This method is worthy of clinical promotion and application.
展开▼
